PF-06741086 Multiple Dose Study in Severe Hemophilia
| Status: | Completed |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - 64 |
| Updated: | 12/20/2018 |
| Start Date: | March 8, 2017 |
| End Date: | December 3, 2018 |
A Multicenter, Open-label, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous Or Intravenous Pf-06741086 In Subjects With Severe Hemophilia
This study is designed to evaluate the safety, tolerability, pharmacokinetics,
pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of
PF-06741086 in subjects with severe hemophilia.
pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of
PF-06741086 in subjects with severe hemophilia.
Inclusion Criteria:
- Severe hemophilia A or B (Factor VIII or Factor IX activity ≤ 1%), including patients
with inhibitors to Factor VIII or Factor IX
- Episodic (on-demand) treatment regimen prior to screening
- At least 6 acute bleeding episodes during the 6-month period prior to screening
Exclusion Criteria:
- Known coronary artery, thrombotic, or ischemic disease
- Currently receiving treatment for acute bleeding episodes with APCC and cannot
substitute treatment with rFVIIa
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials